By Daniel Shvartsman
Investing.com -- Stocks in focus in pre-market trade on Tuesday, December 28th. Prices as of 8:30am ET, please refresh to see updated pricing.
Tesla (NASDAQ:TSLA) traded up 1.8% after getting a price target hike from both Wedbush and Argus gave the electric vehicle leader another charge. Wedbush's Daniel Ives argues the EV sector is set for a significant step forward and Tesla's navigation of the semiconductor supply chain issues puts it in a position of strength. It's not all sunshine for EV related companies, with Lucid Group Inc (NASDAQ:LCID)down 1.2% pre-market. Nvidia (NASDAQ:NVDA) and AMD appear poised to lead semiconductors higher again, as they are trading up 1.4% and 1.2% respectively in the pre-market session. Apple (NASDAQ:AAPL) is also up .2% in pre-market trading despite continued Covid-related store closures. The tech leader is just off of both all-time highs and the shiny $3 Trillion market cap barrier. Albemarle Corp (NYSE:ALB) is up nearly 2% and MercadoLibre Inc (NASDAQ:MELI) is up 1.5%. Peloton Interactive Inc (NASDAQ:PTON) is on watch after a Raymond James analyst called this fiscal year's guidance aggressive even after the most recent quarter's drop. Aaron Kessler said there was "continued softness in the December quarter", and rates Peloton a Market Perform. F5 Networks Inc (NASDAQ:FFIV) is up 1% in thin trading after Needham & Company called it their best idea in networking for 2022, raising the price target to $303 from $266 (and the current share price of $245). Alex Henderson lauded the company's software transition and said it was "becoming a Cloud/Kubernetes play" that would merit a higher multiple. BiondVax Pharmaceuticals Ltd ADR (NASDAQ:BVXV) is poised to rebound from yesterday's share offering induced sell-off, as it is up 38% in busy pre-market trading. Mercury Systems Inc (NASDAQ:MRCY) looks set to open higher after announcing the adoption of a "poison pill" shareholder rights plan in response to activist Jana Partners' 6.6% stake in the business. Vipshop Holdings Limited (NYSE:VIPS) was down 2.2% after cutting its guidance for the current quarter. Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) is down 16% pre-market after its Phase 3 trial of mavrilimumab as a treatment for Covid-19 related acute respiratory syndrome did not meet the primary efficacy endpoint.